{"id":5978,"date":"2025-03-20T12:52:21","date_gmt":"2025-03-20T17:52:21","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5978"},"modified":"2025-07-13T15:10:24","modified_gmt":"2025-07-13T20:10:24","slug":"nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/","title":{"rendered":"Nanoscope Therapeutics anuncia el nombramiento de Ademola Daramola, D.Sc., como vicepresidente de Calidad y Cumplimiento."},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<div class=\"col-sm-4 col-xs-12 col-vcenter\">\n<div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">20 de marzo de 2025<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con la restauraci\u00f3n de la visi\u00f3n en pacientes ciegos en entornos del mundo real mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que\u00a0<span class=\"xn-person\">Ademola Daramola<\/span>El Dr. Daramola, doctor en ciencias, se ha incorporado a la empresa como vicepresidente de Calidad y Cumplimiento. Cuenta con m\u00e1s de dos d\u00e9cadas de experiencia en el desarrollo de procesos y la gesti\u00f3n de flujos de trabajo para una amplia gama de aseguramiento de la calidad, cumplimiento normativo y excelencia operativa en medicamentos, vacunas y dispositivos m\u00e9dicos de uso humano.<\/p>\n<p>\u201cAdemola es un l\u00edder consumado en garant\u00eda de calidad y cumplimiento en diferentes funciones, con una amplia experiencia en la industria farmac\u00e9utica, incluso con la FDA\u201d, dijo\u00a0<span class=\"xn-person\">Sulagna Bhattacharya<\/span>, cofundador y director ejecutivo de Nanoscope. \u201cSu experiencia ser\u00e1 invaluable a medida que avanzamos hacia la comercializaci\u00f3n de nuestras terapias optogen\u00e9ticas\u201d.\u201d<\/p>\n<p>El Dr. Daramola cuenta con una amplia experiencia liderando equipos multifuncionales, desarrollando procesos y gestionando flujos de trabajo para una amplia gama de programas de garant\u00eda de calidad y cumplimiento en las industrias farmac\u00e9utica y de dispositivos m\u00e9dicos. M\u00e1s recientemente, se desempe\u00f1\u00f3 como L\u00edder de Cumplimiento de Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF) para el Instituto de Investigaci\u00f3n M\u00e9dica Bill &amp; Melinda Gates, donde fue responsable de garantizar que los productos biol\u00f3gicos, vacunas y mol\u00e9culas peque\u00f1as de resonancia magn\u00e9tica de Gates, fabricados en instalaciones de terceros, cumplieran con las regulaciones de calidad y seguridad requeridas. Anteriormente, fue Vicepresidente y Director Global de Calidad y Cumplimiento para CIPLA. El Dr. Daramola trabaj\u00f3 casi ocho a\u00f1os en la FDA como Especialista en Relaciones Internacionales y Oficial de Seguridad del Consumidor para Medicamentos y Dispositivos M\u00e9dicos. Comenz\u00f3 su carrera como qu\u00edmico en Teva Pharmaceuticals. El Dr. Daramola obtuvo su doctorado y maestr\u00eda en Salud Global de\u00a0<span class=\"xn-org\">Universidad Nova Southeastern<\/span>. Tiene una Licenciatura en Tecnolog\u00eda de\u00a0<span class=\"xn-org\">Universidad de Barry<\/span>, as\u00ed como una Licenciatura en Ciencias de la Universidad Estatal de Ondo en\u00a0<span class=\"xn-location\">Nigeria<\/span>.<\/p>\n<p>\u201cNanoscope se encuentra en un punto de inflexi\u00f3n importante, tanto en su crecimiento como empresa como con su principal candidato, MCO-010\u201d, declar\u00f3 el Dr. Daramola. \u201cMe entusiasma trabajar con este equipo din\u00e1mico y talentoso, y espero garantizar los m\u00e1s altos est\u00e1ndares de calidad y cumplimiento normativo a medida que llevamos estas terapias que cambian la vida de los pacientes\u201d.\u201d<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n, independientes de las mutaciones, para los millones de pacientes con ceguera causada por enfermedades degenerativas de la retina para las que actualmente no existe tratamiento. Tras los resultados positivos del estudio final de la fase RESTORE,\u00a0<span class=\"xn-money\">2b<\/span>\u00a0ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer semestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>Tambi\u00e9n en el primer semestre de 2025, MCO-010 ha recibido las designaciones de v\u00eda r\u00e1pida de la FDA y de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un activo MCO-020 de administraci\u00f3n l\u00e1ser no viral, listo para IND, para AG, as\u00ed como un activo AAV para la amaurosis cong\u00e9nita de Leber, en estudios que facilitan IND.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0March 20, 2025\u00a0 \u2014 Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that\u00a0Ademola Daramola, D.Sc., has joined the company as Vice President, Quality and Compliance. Dr. Daramola has more than two decades of experience [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5979,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality &amp; Compliance - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality &amp; Compliance - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T17:52:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:10:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality &#038; Compliance\",\"datePublished\":\"2025-03-20T17:52:21+00:00\",\"dateModified\":\"2025-07-13T20:10:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_AdeDaramola_V1_REV2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/\",\"name\":\"Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality & Compliance - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_AdeDaramola_V1_REV2.jpg\",\"datePublished\":\"2025-03-20T17:52:21+00:00\",\"dateModified\":\"2025-07-13T20:10:24+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_AdeDaramola_V1_REV2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_AdeDaramola_V1_REV2.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/20\\\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality &#038; Compliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia el nombramiento de Ademola Daramola, D.Sc., como Vicepresidente de Calidad y Cumplimiento Normativo.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality & Compliance - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-03-20T17:52:21+00:00","article_modified_time":"2025-07-13T20:10:24+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality &#038; Compliance","datePublished":"2025-03-20T17:52:21+00:00","dateModified":"2025-07-13T20:10:24+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/"},"wordCount":502,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/","url":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/","name":"Nanoscope Therapeutics anuncia el nombramiento de Ademola Daramola, D.Sc., como Vicepresidente de Calidad y Cumplimiento Normativo.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg","datePublished":"2025-03-20T17:52:21+00:00","dateModified":"2025-07-13T20:10:24+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_AdeDaramola_V1_REV2.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/20\/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality &#038; Compliance"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5978"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5978\/revisions"}],"predecessor-version":[{"id":7221,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5978\/revisions\/7221"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5979"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}